Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 7/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.52 |
| ▸ | NPY1R | P25929 | 6/20 | 0.52 |
| ▸ | NPY2R | P49146 | 4/20 | 0.52 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.52 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599003 | 0.91 | CCNA2 (0.51) | NPY4RNPY5RNPY1RNPY2RGLP1R | |
| SCHEMBL30101001 | 0.89 | VIPR2 (0.47) | VIPR2VIPR1GLP1R | |
| SCHEMBL6035701 | 0.87 | OPRM1 (0.58) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL29445552 | 0.86 | GLP1R (0.55) | GLP1R | |
| SCHEMBL30419550 | 0.86 | GLP1R (0.55) | GLP1R | |
| SCHEMBL31643038 | 0.86 | GLP1R (0.42) | NPY4RNPY5RNPY1RNPY2RVIPR2 | |
| SCHEMBL31232533 | 0.85 | VIPR2 (0.51) | VIPR2VIPR1GLP1R | |
| SCHEMBL29797106 | 0.85 | KEAP1 (0.54) | VIPR2VIPR1GLP1R | |
| SCHEMBL14921120 | 0.85 | VIPR2 (0.44) | NPY4RNPY5RNPY1RNPY2RVIPR2 | |
| SCHEMBL29659733 | 0.85 | C5AR1 (0.53) | NPY4RNPY5RNPY1RNPY2RVIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403118-B1 | Cancer treatments using modified fatty acids and the carriers to administer them | Zetagen Therapeutics, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403118-B1 | Cancer treatments using modified fatty acids and the carriers to administer them | PAK4, FFAR4, PIK3R4 | NPY4R 430/4885NPY5R 2133/4885NPY1R 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.